Back to Trials
NCT06490146RecruitingAccepts Healthy Volunteers

Menopause Transition, Sex Hormone Deficiency and Autonomic and Vascular Function

University of Minnesota

Start Date

4/1/2025

Completion Date

8/21/2030

Summary

This is a longitudinal study to determine the influence of the menopause transition on autonomic and vascular function. PI Keller-Ross has published data demonstrating that postmenopausal females have greater sympathetic neural reactivity during a stressor compared with age-matched males and younger females and males. A paucity of literature exists, however, on the role of the menopause transition in autonomic function because the majority of experimental studies on menopause physiology are cross-sectional and/or focused on older, postmenopausal females . The influence of age on HTN is robust, whereas the effects of menopause are still unclear. Preliminary data demonstrate a clear association between age and sympathetic activity in females; how the transition through menopause influences these relations, however, remains unknown. The study will enroll 80 midlife (45-55 years of age) females to measure longitudinally the trajectory of autonomic and vascular function during the transition through menopause. The study hypothesizes that through the menopause transition, an increase in sympathetic activity and an impaired baroreflex sensitivity and endothelial function will emerge.

Eligibility Criteria

Age Range: 45 years to 55 years

Inclusion Criteria: * Female * age 45-55 years * premenopausal * not using any medications determined to affect autonomic function * eumenorrheic * not planning to become pregnant for the duration of participation in the study * English-speaking, literate, willing and able to provide informed consent. Exclusion Criteria: * Diabetes * pregnant or breastfeeding * cardiac or pulmonary disorders * severe obesity (body mass index \[BMI\] ≥ 40 kg/m 2 ) * hypertension * obstructive sleep apnea * current use of heart or blood pressure medications, current use of hormonal contraceptives or other forms of exogenous sex hormones * report of nicotine/tobacco use in the last six months, report of current alcohol abuse, * history of treatment with chemotherapy/radiation * coagulopathy disorders and/or use of anticoagulant medications, and current use of anxiolytics and/or antidepressants.

Interventions

OTHER

No intervention

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Menopause

Locations

University of Minnesota

Minneapolis, Minnesota 55414

United States